Sirolimus may prevent the progression of COVID-19 to severe forms by downregulating the senescence-associated secretory phenotype (SASP), mTOR-NLRP3-IL-1β axis, IL-6 pathway, and the number of senescent T cells (26). This evidence concerns the gene IL1B and COVID-19.